Kazia Therapeutics Says Paxalisib Phase 1b Data In Six Evaluable Stage IV Triple-Negative Breast Cancer Patients Showed 83% Objective Response Rate, No Treatment-Related Serious Adverse Events

뉴스 본문을 불러오고 있어요.

Kazia Therapeutics Says Paxalisib Phase 1b Data In Six Evaluable Stage IV Triple-Negative Breast Cancer Patients Showed 83% Objective Response Rate, No Treatment-Related Serious Adverse Events | 웨이프 WAPE

Kazia Therapeutics Says Paxalisib Phase 1b Data In Six Evaluable Stage IV Triple-Negative Breast Cancer Patients Showed 83% Objective Response Rate, No Treatment-Related Serious Adverse Events

기사 요약

관련 종목

댓글 —